info@seagull-health.com
SeagullHealth
search
palbociclib(Ibrance)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Ibrance(palbociclib) Instructions:Uses,Dosage, Side Effects
IBRANCE (palbociclib) is an orally administered kinase inhibitor formulated as capsules. It functions by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators of cell cycle progression.
It is indicated for use in combination with specific endocrine therapies for the treatment of advanced breast cancer. The product is supplied in three dosage strengths.
In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men.
In combination with fulvestrant in patients with disease progression following endocrine therapy.
In combination with inavolisib and fulvestrant for the treatment of endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Recommended starting dose: 125 mg orally once daily with food for 21 days, followed by 7 days off.
Dose adjustments may be required based on hematologic and non-hematologic toxicities.
Avoid concomitant use with strong CYP3A inhibitors or inducers.
For patients with severe hepatic impairment (Child-Pugh Class C), the recommended dose is 75 mg once daily.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
